Media Release Archive 2006

New prostate cancer marker helps identify men whose cancer is likely to spread

04 Oct 2006

Traditional Chinese medicine for diabetes has scientific backing

01 Aug 2006

Reports of a traditional Chinese medicine having beneficial effects for people suffering from type 2 diabetes now has some scientific evidence to back up the claims. A collaboration between Chinese, Korean, and Australian scientists at Sydney’s Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment.

Asthma - Obesity Link : protein linked to diabetes & obesity now has new role in controlling airway inflammation in asthma

15 Jul 2006

A new asthma gene provides an unexpected link between asthma and obesity according to a research team at Sydney’s Garvan Institute, who are also part of the Cooperative Research Centre for Asthma and Airways. Bennett Shum and colleagues have found that a fatty acid binding protein called aP2, which is already known for its role in diabetes and obesity, is also present in the lung where it is crucial in controlling inflammation in asthma.

Cancer cells suppress large regions of DNA by a reversible process that can be tackled with new therapies

25 Apr 2006

Cancer researchers at Sydney’s Garvan Institute, in collaboration with Spanish scientists, have formulated a new concept for how cancer cells can escape normal growth controls, which may have far-reaching implications for the new generation of cancer therapies.

Sydney scientists discover & license breakthrough anti-inflammatory treatment

09 Feb 2006

Scientists from the Garvan Institute of Medical Research have developed what could be the next big blockbuster treatment for inflammatory diseases such as rheumatoid arthritis and asthma. This discovery is being commercialised by G2 Therapies Ltd, a biotechnology company founded by Garvan, which today announced the signing of an AU$135 million research, development and licensing agreement with Danish healthcare company, Novo Nordisk.